HEALEY ALS Platform Trial - Master Protocol (NCT04297683)

🧪 Interventions in This Study

• Zilucoplan (DRUG)
• Verdiperstat (DRUG)
• CNM-Au8 (DRUG)
• Pridopidine (DRUG)
• SLS-005 Trehalose (DRUG)
• ABBV-CLS-7262 (DRUG)
• DNL343 (DRUG)
• NUZ-001 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (81 Sites)

Showing the first 25 of 81 sites.

• Barrow Neurological Institute — Phoenix, Arizona
• Mayo Clinic Scottsdale — Scottsdale, Arizona
• University of Arkansas for Medical Sciences — Little Rock, Arkansas
• UC San Diego — La Jolla, California
• Loma Linda University Health — Loma Linda, California
• Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
• University of Southern California — Los Angeles, California
• Cedars-Sinai Medical Center — Los Angeles, California
• University of California, Irvine — Orange, California
• Forbes Norris MDA/ALS Research Center, California Pacific Medical Center — San Francisco, California
• University of California, San Francisco — San Francisco, California
• University of Colorado — Aurora, Colorado
• Hospital for Special Care — New Britain, Connecticut
• Yale University — New Haven, Connecticut
• Georgetown University — Washington D.C., District of Columbia
• George Washington University — Washington D.C., District of Columbia
• Nova Southeastern University — Davie, Florida
• University of Florida — Gainesville, Florida
• Mayo Clinic Florida — Jacksonville, Florida
• University of Miami — Miami, Florida
• University of South Florida — Tampa, Florida
• Augusta University — Augusta, Georgia
• Saint Alphonsus Regional Medical Center — Boise, Idaho
• Northwestern University — Chicago, Illinois
• University of Chicago — Chicago, Illinois

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Amyotrophic Lateral Sclerosis

• Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) — Toronto, Ontario
• Regulatory T Cells for Amyotrophic Lateral Sclerosis — New York, New York
• Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) — Phoenix, Arizona
• TRIAL READY (Clinical Trial Readiness) — Miami, Florida
• Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment — Phoenix, Arizona
• Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS — New York, New York

Explore by condition: All Amyotrophic Lateral Sclerosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.